141 related articles for article (PubMed ID: 27266040)
1. [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: III. Relation with Type II diabetes: regulation by hepatokines].
Misu H
Nihon Naika Gakkai Zasshi; 2016 Jan; 105(1):25-30. PubMed ID: 27266040
[No Abstract] [Full Text] [Related]
2. Hepatokines and non-alcoholic fatty liver disease.
Lebensztejn DM; Flisiak-Jackiewicz M; Białokoz-Kalinowska I; Bobrus-Chociej A; Kowalska I
Acta Biochim Pol; 2016; 63(3):459-67. PubMed ID: 27262842
[TBL] [Abstract][Full Text] [Related]
3. Identification of hepatokines involved in pathology of type 2 diabetes and obesity.
Misu H
Endocr J; 2019 Aug; 66(8):659-662. PubMed ID: 31366824
[TBL] [Abstract][Full Text] [Related]
4. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Meex RCR; Watt MJ
Nat Rev Endocrinol; 2017 Sep; 13(9):509-520. PubMed ID: 28621339
[TBL] [Abstract][Full Text] [Related]
5. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
[No Abstract] [Full Text] [Related]
6. Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India.
Dutta D; Mondal SA; Kumar M; Hasanoor Reza AH; Biswas D; Singh P; Chakrabarti S; Mukhopadhyay S
Diabet Med; 2014 Dec; 31(12):1594-9. PubMed ID: 24975463
[TBL] [Abstract][Full Text] [Related]
7. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
8. A biochemical view: Increase in polyunsaturated fatty acid ω-6/ω-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease.
Sertoglu E; Kayadibi H; Uyanik M
J Diabetes Complications; 2015; 29(1):157. PubMed ID: 25455415
[No Abstract] [Full Text] [Related]
9. Role of exercise-induced hepatokines in metabolic disorders.
Ennequin G; Sirvent P; Whitham M
Am J Physiol Endocrinol Metab; 2019 Jul; 317(1):E11-E24. PubMed ID: 30964704
[TBL] [Abstract][Full Text] [Related]
10. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
11. New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease.
Matsuzaka T; Shimano H
J Diabetes Investig; 2020 May; 11(3):532-534. PubMed ID: 32232972
[TBL] [Abstract][Full Text] [Related]
12. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans.
Peter A; Kovarova M; Staiger H; Machann J; Schick F; Königsrainer A; Königsrainer I; Schleicher E; Fritsche A; Häring HU; Stefan N
Am J Physiol Endocrinol Metab; 2018 Mar; 314(3):E266-E273. PubMed ID: 29138227
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
14. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
[TBL] [Abstract][Full Text] [Related]
17. The role of hepatokines in metabolism.
Stefan N; Häring HU
Nat Rev Endocrinol; 2013 Mar; 9(3):144-52. PubMed ID: 23337953
[TBL] [Abstract][Full Text] [Related]
18. Alterations in serum levels of fetuin A and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: A case-control study.
Ali SA; Nassif WM; Abdelaziz DH
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):465-70. PubMed ID: 26823042
[TBL] [Abstract][Full Text] [Related]
19. Fetuin-A: a novel link between obesity and related complications.
Trepanowski JF; Mey J; Varady KA
Int J Obes (Lond); 2015 May; 39(5):734-41. PubMed ID: 25468829
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic steatohepatitis and diabetes.
Caballeria J; Caballeria L
Endocrinol Nutr; 2016 Oct; 63(8):377-9. PubMed ID: 27423933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
